Dr. Jeremy Baldwin, Postdoctoral Scientist in the Functional Immune Cell Modulation Division of the LIT, received an Add-on Fellowships for Interdisciplinary Life Science of 12.500€ by the Joachim Herz Foundation for his research project on metabolically reprogramming CD8+ T cells for cancer immunotherapy applications.
Peter Aumer and Katrin Staffler, members of the German Bundestag, visited the LIT on January 24, 2024.
Researchers at the Leibniz Institute for Immunotherapy (LIT) have demonstrated that killer T cells of the immune system not only eliminate pathologically altered cells, but also promote the subsequent tissue wound healing process.
Professor Hendrik Poeck receives EU funding of 2 million euros for his research on immunotherapies in leukemia patients. The ERC Consolidator Grant will fund his research for a period of five years.
The Scientific Director of the Leibniz Institute for Immunotherapy (LIT), Prof. Philipp Beckhove, visited the German Bundestag. The attending deputies were impressed by the excellent research conducted at LIT. Subsequently, possibilities were discussed to enhance the international competitiveness of biomedical research in Germany.
The former Bavarian State Minister for Science and the Arts, Dr. Thomas Goppel, and Ministerial Councilor Florian Albert visited on September 21, 2023, to get information about the latest developments in immunological research at LIT.
The award-winning work from Dr. Christian Schmidl’s group investigates epigenetic changes in tumor-infiltrating T cells that distinguish functional from dysfunctional (“exhausted”) T cells.
Partners in the international consortium CAR T-REX announce the awarding of a highly competitive EIC Pathfinder Open grant, following the positive evaluation of their project entitled ‘CAR T Cells Rewired to Prevent EXhaustion in the Tumour Microenvironment’.
The prestigious Johann Georg Zimmermann Medal was awarded this year to LIT scientist Prof. Hinrich Abken in recognition of his lifetime achievements.
T cells, working within our immune system, can potentially infiltrate tumors and kill cancer cells. But they often get worn out or ‘exhausted,’ which puts the anti-cancer immune reaction on hold.